Published in Int J Pharm on May 25, 2010
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release (2011) 1.05
Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother (2011) 0.92
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother (2012) 0.82
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res (2010) 1.24
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res (2013) 1.12
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses (2013) 1.04
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci (2011) 1.01
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
Multipurpose prevention technologies: products in development. Antiviral Res (2013) 1.00
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci (2007) 0.97
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res Hum Retroviruses (2012) 0.90
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures. J Acquir Immune Defic Syndr (2015) 0.89
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release (2012) 0.87
Measuring macrodiffusion coefficients in microbicide hydrogels via postphotoactivation scanning. Biomacromolecules (2008) 0.87
Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. Mol Pharm (2010) 0.85
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm (2011) 0.84
Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials (2011) 0.84
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine. Drug Deliv Transl Res (2011) 0.83
Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel. Drug Deliv Transl Res (2011) 0.82
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm (2011) 0.82
Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Deliv Transl Res (2011) 0.81
Intravaginal flux controlled pump for sustained release of macromolecules. Pharm Res (2014) 0.81
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81
Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res (2013) 0.79
Chemorheology of phenylboronate-salicylhydroxamate crosslinked hydrogel networks with a sulfonated polymer backbone. Macromolecules (2008) 0.79
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS (2016) 0.79
Preclinical evaluation of UC781 microbicide vaginal drug delivery. Drug Deliv Transl Res (2011) 0.78
Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J Pharm Sci (2013) 0.78
Specific covalent immobilization of proteins through dityrosine cross-links. Langmuir (2006) 0.77
Site-specific cross-linking of proteins through tyrosine hexahistidine tags. Bioconjug Chem (2005) 0.77
Development of a UC781 releasing polyethylene vinyl acetate vaginal ring. Drug Deliv Transl Res (2012) 0.76
Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Eur J Pharm Biopharm (2013) 0.75
Correction: Musosal effects for tenofovir 1% gel. Elife (2015) 0.75
Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques. Drug Deliv Transl Res (2015) 0.75
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. J Biomed Mater Res B Appl Biomater (2012) 0.75